How long does 2-FA last?

The total duration of 2-FA via oral is 2 hours to 4 hours. Onset typically occurs within 15 minutes to 30 minutes. Peak effects last 1 hour to 2 hours.

2-FA — SubstanceWiki

2-Fluoroamphetamine
2-Fluoroadenine

Topics referred to by the same termThis disambiguation page lists articles associated with the same title formed as a letter–number combination. If an internal link incorrectly led you here, you may wish to change the link to point directly to the intended article.

Retrieved from "https://en.wikipedia.org/w/index.php?title=2-FA&oldid=1244921699" Category: - Letter–number combination disambiguation pages

Hidden categories: - Short description is different from Wikidata

All article disambiguation pages
All disambiguation pages
This page was last edited on 9 September 2024, at 23:50(UTC).
Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Legal & safety contacts
Code of Conduct
Developers
Statistics
Cookie statement
Mobile view

2-FA

Add languages

Add topic

How It Feels

The onset of 2-FA unfolds with a clean, purposeful quality. Within thirty to forty-five minutes of oral ingestion, a measured wave of alertness rises through the body. There is no dramatic rush, but rather a smooth engagement of the mental machinery. The mind sharpens, the eyes focus with slightly more precision, and there is a building sense of readiness, as though the brain has been quietly cleared of fog and clutter.

As the effects reach full expression over the next hour, 2-FA reveals its character as a functional, no-nonsense stimulant. Focus intensifies in a way that feels organic rather than forced. Sustained attention becomes easier, and the motivational threshold for beginning tasks drops noticeably. Conversations are fluid and purposeful without the compulsive talkativeness of more euphoric stimulants. The body feels alert and capable. Heart rate increases modestly, appetite recedes into the background, and there is a mild peripheral vasoconstriction that may leave the hands slightly cool. The jaw may clench lightly, but the physical side effects remain subtle and manageable.

At the peak, typically two to three hours in, the experience is defined by its transparency. The stimulation integrates so smoothly into normal functioning that it can be easy to forget you have taken anything at all, were it not for the unusual ease with which you move through tasks that would ordinarily require willpower. There is a mild mood elevation, an optimistic confidence that stays well within the bounds of normalcy. The euphoria, if it can be called that, is more the quiet satisfaction of productive work than any kind of neurochemical fireworks.

The offset is gradual, extending over three to four hours as the focused energy slowly ebbs. There is a mild fatigue as the drug clears, a gentle reminder that you have been operating at an elevated baseline, but the landing is soft. Appetite returns, the jaw relaxes, and sleep, while perhaps slightly delayed, arrives without significant difficulty. The total duration of six to eight hours and the absence of a harsh comedown give 2-FA its reputation as one of the more practical and workmanlike compounds in the fluorinated amphetamine family.

Pharmacology

Although 2-FA has not been formally studied on the same level as traditional amphetamines, it is safe to assume that just like other substituted amphetamines with substitutions at similar positions (with the notable exception of 4-FA), it most likely acts primarily as both a dopamine and norepinephrine releasing agent. This means it effectively increases the levels of the norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally clear those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain to extra-endogenous levels, resulting in stimulating, motivating and euphoric effects.

In comparison to other substituted amphetamines, 2-FA is reported to be relatively free of side effects such as nausea, high blood pressure, anxiety and an uncomfortable offset ("comedown"). It is considered to be a functional and effective psychoactive substance for performing general productivity tasks in a manner that is similar to dextroamphetamine. However, at higher doses, it reportedly loses its productivity and attention-enhancing effects and begins to take on a recreational character due to the distracting euphoria and overstimulation that can result. However, it is often said that it possesses a "ceiling dose" that purportedly lowers the abuse threshold relative to methamphetamine, although this has yet to be scientifically demonstrated.

The toxicity and long-term health effects of recreational 2-exact toxic dosage is unknown. This is because 2-FA has very little history of human usage. Anecdotal evidence from people who have tried 2-FA within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Others have commented that its d-isomer form is virtually similar to the effects of d-amphetamine, and thus far little has been shown to give reason to suspect that its toxicity is radically different (though future evidence to the contrary may prove otherwise).

It is perhaps worth noting that in the field of medicinal chemistry, the fluorine substitution is sometimes seen as desirable in central nervous system pharmaceutical agents, and is a common practice due to the corresponding increase in lipophilicity granted by the substitute.

It is strongly recommended that one use harm reduction practices when using this drug.

As with other stimulants, the chronic use of 2-moderately addictive with a high potential for abuse and is capable of causing psychological dependence among a certain population of users. When dependence or addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 2-develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 10 days to be back at baseline (in the absence of further consumption). 2-FA presents cross-tolerance with Cross-all dopaminergic stimulants, meaning that after the consumption of 2-FA all stimulants will have a reduced effect (especially including atypical stimulants one might not expect, like MDMA due to its reliance on dopamine and norepinephrine to exert its full euphoric effect).

In a analogous way tolerance to amphetamine relates to tolerance on methamphetamine, 2-FA has been observed to have a similar relationship to its more popular relative, 2-FMA.

Psychosis

Abuse of compounds within the amphetamine chemical class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions). A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely. The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.

2-FA is currently a grey area compound within all parts of the world, meaning its regulation lies in a legal grey area and that it is not known to be specifically illegal ("scheduled") within any country. However, people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.

Canada: 2-FA would be considered Schedule I as it is an analogue of Amphetamine.
China: As of October 2015 2-FA is a controlled substance in China.
France: As of december 2024, 2-FA is not explicitly scheduled. It is thus legal to possess, although in a grey area.
Germany: 2-FA is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
New Zealand: 2-FA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.
Switzerland: 2-FA is a controlled substance specifically named under Verzeichnis E.
Turkey:** 2-FA is a classed as drug and is illegal to possess, produce, supply, or import.
The Netherlands:** 3-FA is a controlled substance as of July 1, 2025.
United Kingdom: 2-FA is considered a Class A drug as a result of the amphetamine analog clause of the Misuse of Drugs Act 1971.
United States: 2-FA may be considered to be an analogue of amphetamine under the Federal Analogue Act and thus a Schedule II drug. The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act, allowing any chemical "substantially similar" to an illegal drug (in Schedule I or II) to be treated as if it were also in Schedule I or II, but only if it is intended for human consumption.
Responsible use
Designer drug
Stimulants
Substituted amphetamine
Amphetamine
2-FMA
3-FA
4-FA
2-FA (Wikipedia)
2-FA (Isomer Design)

Detection Methods

Standard Drug Panel Inclusion

2-FA (2-Fluoroamphetamine) is a fluorinated amphetamine analogue that is generally not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. The fluorine substitution on the phenyl ring alters the molecular structure sufficiently that most amphetamine-targeted antibodies in commercial immunoassays fail to recognize it. However, cross-reactivity varies between manufacturers and assay generations, so a false positive on the amphetamine channel cannot be entirely ruled out.

Urine Detection

Due to the structural similarity to amphetamine, 2-FA (2-Fluoroamphetamine) and its metabolites may persist in urine for approximately 2 to 4 days after a single dose. Chronic or heavy use can extend this window. The primary metabolites include deaminated and hydroxylated derivatives, though comprehensive metabolic profiling of 2-FA (2-Fluoroamphetamine) in humans remains limited. Standard immunoassay urine cups will typically return a negative result for 2-FA (2-Fluoroamphetamine) unless the specific assay has unusually broad cross-reactivity.

Blood and Saliva Detection

2-FA (2-Fluoroamphetamine) can be detected in blood and oral fluid for approximately 12 to 48 hours after ingestion. Blood testing is uncommon outside of clinical or forensic contexts. Oral fluid testing follows a similar window but is used primarily in roadside or workplace settings where immediate-use detection is the goal.

Hair Follicle Detection

Hair follicle analysis can theoretically detect 2-FA (2-Fluoroamphetamine) for up to 90 days. However, most commercial hair testing laboratories do not include fluorinated amphetamines in their standard panels. Detection requires specific method development using LC-MS/MS with reference standards for 2-FA (2-Fluoroamphetamine).

Confirmatory Testing

Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the definitive methods for confirming the presence of 2-FA (2-Fluoroamphetamine). These techniques can distinguish 2-FA (2-Fluoroamphetamine) from amphetamine, methamphetamine, and other substituted amphetamines with high specificity. Reference standards for 2-FA (2-Fluoroamphetamine) must be available to the testing laboratory for positive identification.

Reagent Testing

Marquis reagent produces no reaction or a faint orange-brown color with 2-FA (2-Fluoroamphetamine), which differs from the orange-to-brown response seen with standard amphetamine. Mecke reagent typically shows no reaction. Simon's reagent can help differentiate primary amines from secondary amines in the amphetamine class. Mandelin reagent may produce a faint green-brown color. These reagent responses help distinguish 2-FA (2-Fluoroamphetamine) from MDMA, methamphetamine, and cathinones but cannot confirm identity on their own.

Interactions

Substance	Status	Note
Atropa belladonna	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Datura	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Diphenhydramine	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Harmala alkaloid	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Peganum harmala	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
25x-NBOMe	Unsafe	—
2C-T-x	Unsafe	—
DOx	Unsafe	—
PCP	Unsafe	—
1,3-Butanediol	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
25E-NBOH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-2	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-21	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-7	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FMA	Caution	Increased cardiovascular strain and neurotoxicity risk
4-MMC	Caution	Increased cardiovascular strain and neurotoxicity risk
8-Chlorotheophylline	Caution	Increased cardiovascular strain and neurotoxicity risk
Adrafinil	Caution	Increased cardiovascular strain and neurotoxicity risk
Allylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ayahuasca	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Benzydamine	Caution	Increased cardiovascular strain and neurotoxicity risk
Bromantane	Caution	Increased cardiovascular strain and neurotoxicity risk
Cake	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Deschloroetizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Desomorphine	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
DET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dichloropane	Caution	Increased cardiovascular strain and neurotoxicity risk
Diclazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
DiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DOM	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Efavirenz	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ephedrine	Caution	Increased cardiovascular strain and neurotoxicity risk
EPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Eszopiclone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Etizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Gaboxadol	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Hexedrone	Caution	Increased cardiovascular strain and neurotoxicity risk
Ibogaine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Lorazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Mephenaqualone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methallylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increased cardiovascular strain and neurotoxicity risk
Metizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Midazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Naloxone	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
Nicotine	Caution	Increased cardiovascular strain and neurotoxicity risk
Nifoxipam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Oxiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Pentobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenylpiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Psilocybin Mushrooms	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increased cardiovascular strain and neurotoxicity risk
SAMe	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Alcohol	Uncertain	—
Caffeine	Uncertain	—
Cannabis	Uncertain	—
Cocaine	Uncertain	—
GHB	Uncertain	—
Ketamine	Uncertain	—

Showing 69 key interactions out of 72 total.

Toxicity & Safety

Further information: Research chemicals § Toxicity and harm potential The toxicity and long-term health effects of recreational 2-FA use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 2-FA has very little history of human usage. Anecdotal evidence from people who have tried 2-FA within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Others have commented that its d-isomer form is virtually similar to the effects of d-amphetamine, and thus far little has been shown to give reason to suspect that its toxicity is radically different (though future evidence to the contrary may prove otherwise).

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other stimulants, the chronic use of 2-FA can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among a certain population of users. When dependence or addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 2-FA develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 10 days to be back at baseline (in the absence of further consumption). 2-FA presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of 2-FA all stimulants will have a reduced effect (especially including atypical stimulants one might not expect, like MDMA due to its reliance on dopamine and norepinephrine to exert its full euphoric effect).

In a analogous way tolerance to amphetamine relates to tolerance on methamphetamine, 2-FA has been observed to have a similar relationship to its more popular relative, 2-FMA.

Psychosis

Main article: Stimulant psychosis Abuse of compounds within the amphetamine chemical class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions). A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely. The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.Cite error: Closing missing for tag

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Alcohol - Drinking alcohol on stimulants is considered risky because it reduces the sedative effects of the alcohol that the body uses to gauge drunkenness. This often leads to excessive drinking with greatly reduced inhibitions, increasing the risk of liver damage and increased dehydration. The effects of stimulants will also allow one to drink past a point where they might normally pass out, increasing the risk. If you do decide to do this then you should set a limit of how much you will drink each hour and stick to it, bearing in mind that you will feel the alcohol and the stimulant less.
GHB/GBL - Stimulants increase respiration rate allowing a higher dose of sedatives. If the stimulant wears off first then the depressant effects of the GHB/GBL may overcome the user and cause respiratory arrest.
Opioids - Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
Cocaine - The rewarding effects of cocaine are mediated by DAT inhibition, and an increase of exocytosis of dopamine through the cell membrane. Amphetamine reverses the direction of DAT and the direction vesicular transports within the cell by a pH mediated mechanism of displacement, thus excludes the regular mechanism of dopamine release through means of exocytosis because the effects Na+/K+ ATPase are inhibited. You will find cardiac effects with the combination of cocaine and amphetamine due to a SERT mediated mechanism from the subsequent activation of 5-HT2B, which is an effect of serotonin-related valvulopathy. Amphetamines generally cause hypertension in models of abuse, and this combination can increase the chances of syncope due to turbulent blood flow during valve operation. The rewarding mechanisms of cocaine are reversed by administration of amphetamine.
Cannabis - Stimulants increase anxiety levels and the risk of thought loops and paranoia which can lead to negative experiences.
Caffeine - This combination of stimulants is generally considered unnecessary and may increase strain on the heart, as well as potentially causing anxiety and physical discomfort.
Tramadol - Tramadol and stimulants both increase the risk of seizures.
DXM - Both substances raise heart rate, in extreme cases, panic attacks caused by these substances have led to more serious heart issues.
Ketamine - Combining amphetamine and ketamine may result in psychoses that resemble schizophrenia, but not worse than the psychoses produced by either substance alone, but this is debatable. This is due to amphetamines ability to attenuated the disruption of working memory caused by ketamine. Amphetamine alone may result in grandiosity, paranoia, or somatic delusions with little to no effect on negative symptoms. Ketamine, however, will result in thought disorders, disruption of executive functioning, and delusions due to a modification of conception. These mechanisms are due to an increase of dopaminergic activity in the mesolimbic pathway caused by amphetamine due to its pharmacology effecting dopamine, and due to a disruption of dopaminergic functioning in the mesocortical pathways via NMDA antagonism effects of ketamine. Combining the two, you may expect mainly thought disorder along with positive symptoms.
PCP - Increases risk of tachycardia, hypertension, and manic states.
Methoxetamine - Increases risk of tachycardia, hypertension, and manic states.
Psychedelics (e.g. LSD, mescaline, psilocybin) - Increases risk of anxiety, paranoia, and thought loops.
25x-NBOMe - Amphetamines and NBOMes both provide considerable stimulation that when combined they can result in tachycardia, hypertension, vasoconstriction and, in extreme cases, heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
2C-T-x - Suspected of mild MAOI properties. May increase the risk of hypertensive crisis.
5-MeO-xxT - Suspected of mild MAOI properties. May increase the risk of hypertensive crisis.
DOx
aMT - aMT has MAOI properties which may interact unfavorably with amphetamines.
MAOIs - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably. MAO-A inhibitors with amphetamine can lead to hypertensive crises.

Addiction Potential

moderately addictive with a high potential for abuse

Overdose Information

Stimulant overdose from 2-FA is a medical emergency primarily involving cardiovascular and neurological toxicity.

Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.Emergency response:

Call emergency services immediately
Keep the person cool (remove excess clothing, apply cool water)
If seizures occur, protect the head and clear the area of hard objects
If the person loses consciousness, place in recovery position
Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionalsPrevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.

2-FA

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(5)

Cognitive & Perceptual Effects

Cognitive(3)

Pharmacology

Detection Methods

Standard Drug Panel Inclusion

Urine Detection

Blood and Saliva Detection

Hair Follicle Detection

Confirmatory Testing

Reagent Testing

Interactions

History

Harm Reduction

Toxicity & Safety

Addiction Potential

Overdose Information

Dangerous Interactions

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (4)

See Also

References (3)

Frequently Asked Questions

Full	develops with prolonged and repeated use
Half	3 - 7 days
Zero	1 - 10 days